Evidence map›Paper›PMID 40005492›Full record

ArticlePathogens (Basel, Switzerland)2025

Prevalence of

Helena Schirmer, Camila Henriques, Helena Simões, Cristina Veríssimo, Raquel Sabino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Helena SchirmerDepartment of Basics Health Sciences, Federal University of Health and Sciences of Porto Alegre (UFCSPA), Porto Alegre 90050-170, Brazil.ORCID 0000-0002-8979-9343
Camila HenriquesNational Reference Laboratory for Influenza and Other Respiratory Virus, National Institute of Health Doutor Ricardo Jorge (INSA), 1649-016 Lisbon, Portugal.
Helena SimõesReference Unit for Parasitic and Fungal Infections, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), 1649-016 Lisbon, Portugal.
Cristina VeríssimoReference Unit for Parasitic and Fungal Infections, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), 1649-016 Lisbon, Portugal.ORCID 0000-0002-1169-252X
Raquel SabinoFaculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal.ORCID 0000-0001-6585-7775

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous fungal infections represent a significant burden worldwide with a high impact on public health. Accurate identification of dermatophyte species causing these infections is vital for an appropriate treatment. Terbinafine is the primary agent against

Indexed as

Antifungal AgentsArthrodermataceaeDrug Resistance, FungalTerbinafineTineaTrichophytonHumansMicrobial Sensitivity TestsPortugalPrevalenceAntifungal AgentsTerbinafineantifungal resistancedermatophytessqualene epoxidase mutationsterbinafineTrichophyton

Identifiers

PMID40005492
PMCPMC11858771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.